Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

O'Shaughnessy, 2005, Extending survival with chemotherapy in metastatic breast cancer, Oncologist, 10, 20, 10.1634/theoncologist.10-90003-20 Prat, 2015, Clinical implications of the intrinsic molecular subtypes of breast cancer, Breast, 24, S26, 10.1016/j.breast.2015.07.008 Gong, 2017, Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study, Sci Rep, 7 Baselga, 2012, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, 366, 520, 10.1056/NEJMoa1109653 Finn, 2016, Palbociclib and letrozole in advanced breast cancer, N Engl J Med, 375, 1925, 10.1056/NEJMoa1607303 Cristofanilli, 2016, Lancet Oncol, 17, 425, 10.1016/S1470-2045(15)00613-0 Hortobagyi, 2016, Ribociclib as first-line therapy for hr-positive, advanced breast cancer, N Engl J Med, 375, 1738, 10.1056/NEJMoa1609709 Slamon, 2018, Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3, J Clin Oncol, 36, 2465, 10.1200/JCO.2018.78.9909 Goetz, 2017, MONARCH 3: abemaciclib as initial therapy for advanced breast cancer, J Clin Oncol, 35, 3638, 10.1200/JCO.2017.75.6155 Sledge, 2017, MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy, J Clin Oncol, 35, 2875, 10.1200/JCO.2017.73.7585 Cardoso, 2017, 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3), Ann Oncol, 28, 16, 10.1093/annonc/mdw544 Rugo, 2016, Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline, J Clin Oncol, 34, 3069, 10.1200/JCO.2016.67.1487 Andrè, 2014, Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer, Curr Med Res Opin, 30, 1007, 10.1185/03007995.2014.887002 Bonotto, 2017, Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis, Breast, 31, 114, 10.1016/j.breast.2016.10.021 Cazzaniga, 2017, 259P Adherence to International ESO-ESMO (ABC) guidelines in HER2-ve metastatic breast cancer (MBC) patients (pts): preliminary results of the GIM 13-AMBRA Study, Ann Oncol, 28 Lobbezoo, 2016, In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium, Ann Oncol, 27, 256, 10.1093/annonc/mdv544 Lu, 2004, Combination of direct and indirect evidence in mixed treatment comparisons, Stat Med, 23, 3105, 10.1002/sim.1875 2011 Zhang, 2017, Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: a network meta-analysis, Medicine, 96 Wilson, 2017, Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer, Breast Cancer Res Treat, 166, 167, 10.1007/s10549-017-4404-4 Zhang, 2018, Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis, Onco Targets Ther, 11, 2647, 10.2147/OTT.S165681 Generali, 2015, A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer, Breast Cancer Res Treat, 152, 95, 10.1007/s10549-015-3453-9 Forsythe, 2018, Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer, Breast Cancer, 10, 69 Li, 2017, Progression-free survival and time to progression as real surrogate end points for overall survival in advanced breast cancer: a meta-analysis of 37 trials, Clin Breast Cancer, 18, 63, 10.1016/j.clbc.2017.07.015 Eisenhauer, 2009, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Lunn, 2000, WinBUGS—a Bayesian modelling framework: concepts, structure, and extensibility, Stat Comput, 10, 325, 10.1023/A:1008929526011 André, 2019, Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer, N Engl J Med, 380, 1929, 10.1056/NEJMoa1813904 Dixon, 1992, A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer, Br J Cancer, 66, 402, 10.1038/bjc.1992.277 Jerusalem, 2018, Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor–positive, HER2-negative advanced breast cancer. The BOLERO-6 randomized clinical trial, JAMA Oncol, 4, 1367, 10.1001/jamaoncol.2018.2262 Jacquet, 2018, Endocrine therapy or chemotherapy as first-line therapy in hormone receptor positive HER2-negative metastatic breast cancer patients, Eur J Cancer, 95, 10.1016/j.ejca.2018.03.013 Brodowicz, 2014, Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses, Br J Cancer, 111, 2051, 10.1038/bjc.2014.504 Rugo HS, Barry WT, Moreno-Aspitia A, et al. Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): a randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC). 2017 San Antonio Breast Cancer Symposium; Dec 5–9, 2017; San Antonio, TX; GS3-06 (abstr). Verma, 2018, Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2, Breast Cancer Res Treat, 170, 535, 10.1007/s10549-018-4769-z Rugo, 2019, Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up, Breast Cancer Res Treat, 174, 719, 10.1007/s10549-018-05125-4 Chaimani, 2013, Graphical tools for network meta-analysis in STATA, PLoS One, 8, 10.1371/journal.pone.0076654 Greenland, 1994, Can meta-analysis be salvaged?, Am J Epidemiol, 140, 783, 10.1093/oxfordjournals.aje.a117326 Bailor, 1997, The promise and problems of meta-analysis, N Eng J Med, 337, 559, 10.1056/NEJM199708213370810 Dias, 2018